Herein is reported the design and synthesis of poly(ethylene glycol) derivatives of Lamellarin D with the aim of modulating their physicochemical properties, and improving the biological activity. Mono-, di-and tri-PEG conjugates with improved solubility were obtained in 18-57% overall yields from the corresponding partially Furthermore, cell cycle arrest at G2 phase, and apoptotic cell-death pathways were determined for Lamellarin D and these derivatives.
INTRODUCTION
Compounds with a good therapeutic profile often do not reach the drug market because they show poor pharmacokinetics, mainly due to poor solubility. Attachment of well-defined, water-soluble, biocompatible, non-toxic, and non-immunogenic polymeric systems to drug candidates can overcome this limitation. Furthermore, these chemical water-soluble biocompatible polymers to low molecular weight anti-cancer drugs has been reported to enhance the solubility of the drugs, enhance their accumulation in tumors, and prolong their retention in the circulatory system, thereby improving the drugs' pharmacodynamics and pharmacokinetics (8, 9) . Notwithstanding, further controlled drug delivery by means of a readily hydrolyzable conjugation bond is required for the appropriate release of the bioactive drug (10) . Therefore, modulation of biopolymers that bind drugs is of paramount importance for preclinical research and developments with new lead compounds (11) . Recently, PEGylated compounds used in cancer therapy have been shown to promote the EPR effect (12, 13) , raising the local concentration of drug accumulated in targeted solid tumors. It has been proposed that
Methyl 1-(4-benzyloxy-3-methoxyphenyl)-8-isopropoxy-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate (13a)
A solution of methyl 1-bromo-8-isopropoxy-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate (543 mg, 1.4 mmol) in DMF (40 mL) was purged with Ar, and 2-(4-benzyloxy-3-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (11a) (703 mg, 2.1 mmol), Pd(PPh 3 ) 4 (159 mg, 0.1 mmol) and 2M K 2 CO 3 (2.8 mL, 5.5 mmol)
were added. The reaction mixture was stirred at 125 ºC for 16 h. The solvent was removed after cooling to r.t. and the residue was dissolved in EtOAc. The organic solution was washed with water and brine, dried (MgSO 4 ) and concentrated to give a crude material, which was later purified by column chromatography on silica gel. 
Methyl 1-(4-benzyloxy-3-methoxyphenyl)-2-bromo-8-isopropoxy-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-3-carboxylate (14a)
NBS (82 mg, 0.46 mmol) was added in one portion to a solution of 13a (245 mg, 0.46 mmol) in THF (10 mL 
(s). MS (MALDI-TOF) 615 (M, 100), 616 (M+1, 16).

Methyl 2-(2,4-dihydroxy-5-methoxyphenyl)-1-(4-hydroxy-3-methoxyphenyl)-8-isopropoxy-9-methoxypyrrolo[2,1-a]isoquinoline-3-carboxylate (17c)
Following the general procedure C and starting from 16c (122 mg, 0.14 mmol), a yellow oil (80 mg, 95%) was obtained. 
(s). MS (MALDI-TOF) 583 (M, 100), 58(M+1, 62).
3,11-Diisopropyl-Lam-D (18b)
Following the general procedure D and starting from 17b (365 mg, 0.59 mmol), a yellow solid (346 mg, quant. yield) was obtained. 
11-Isopropyl-Lam-D (18c)
Following the general procedure D and starting from 17c (80 mg, 0.14 mmol), a yellow 
4',11-Diisopropyl-3-(2-(2-(2-methoxyethoxy)ethoxy)acetyl)-Lam-D (19a)
Following the general procedure E and starting from 18a (190 
3,11-Diisopropyl-4'-(2-(2-(2-methoxyethoxy)ethoxy)acetyl)-Lam-D (19c)
Following the general procedure E and starting from 18b (104 mg, 0. 
4'-[3-(2-(2-(2-(2-(2-(2-tert-
Butoxycarbonylaminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)propanoyl]-
3,11-diisopropyl-Lam-D (19d)
Following the general procedure E and starting from 18b (82 mg, 0.14 mmol), a brown 
3-(2-(2-(2-Methoxyethoxy)ethoxy)acetyl)-Lam-D (2)
Following 
3-[3-(2-(2-(2-(2-(2-(2-
Aminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)propanoyl]-Lam-D (3)
Following the general procedure F and starting from 19b (140 mg, 0.14 mmol), elution 
4'-(2-(2-(2-Methoxyethoxy)ethoxy)acetyl)-Lam-D (4)
4'-[3-(2-(2-(2-(2-(2-(2-
Aminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)propanoyl]-Lam-D (5)
3,4'-bis(2-(2-Methoxyethoxy)acetyl)-Lam-D (6)
3,4'-bis(2-(2-(2-Methoxyethoxy)ethoxy)acetyl)-Lam-D (7)
Following the general procedure F and starting from 19f (48 mg, 0.06 mmol), elution with hexane/THF (60:40 to 40:60) gave a white solid (8 mg, 19% µg/mL).
A colorimetric assay using SRB was adapted for a quant. measurement of cell growth and viability, following a previously described method (16) . After 24 h, the culture medium was discarded, and then replaced by fresh DMEM medium containing compound 9 at 25 nM. A negative control (no compound) was also used. The cells were then incubated for 48 h at 37 ºC.
The following dyes were used for co-localization experiments: WGA-FITC (Sigma, 
RESULTS
Lam-D contains three phenolic sites susceptible to modification. Despite previous SAR studies that highlighted the relevance of the phenolic residues at the C-3 and C-11
positions of Lam-D (3, 19) , and their essential role for cytotoxicity and topoisomerase I inhibition (3), in this study, the free OH groups were chosen for attachment the PEG moiety. As esters readily hydrolyze under physiological conditions, our group envisioned that these derivatives would enable gradual release of the drug. Use of Lam-D derivatives having differently protected phenols allowed selective deprotection and further conjugation with PEG-carboxylic acids to enable synthesis of mono-PEG (2-5),
di-PEG (6, 7) and tri-PEG (8, 9) conjugates (Fig. 1) .
The derivatives prepared contain monodisperse PEG backbones with OMe ( As shown in Scheme 1, several dialkoxy and trialkoxy-phenylboronates 11a-b and 12a-b were required. These compounds were obtained with good yields by borylation of the corresponding aryl bromides with pinacolborane using Pd(OAc) 2 and DPE-Phos as catalysts (for details, see Supporting Information). The protected alkoxy-aryl bromides required were obtained by protection of commercially available phenols followed by mild bromination via NBS in THF at -78 ºC (20) .
Regioselective bromination of 10 (21) at position 1 using one equivalent of NBS in THF followed by Pd(0)-catalyzed cross-coupling reaction with the boronic ester 11a or 11b afforded the monoaryl scaffolds 13a and 13b (15) , respectively, which were converted into the bromides 14a, 14b (15) by regioselective bromination at position 2.
A second cross-coupling reaction, using the trialkoxyphenylboronates 12a or 12b, gave Lastly, the conjugates were further evaluated biologically and in vitro drug delivery assays were carried out.
Cytotoxicity and Cellular Uptake. corresponding to 9 was observed in the cytoplasm; 4 however, no fluorescence was observed in the nuclear region of any of the cells for compound 9 (Fig. 2) .
The internalization of compounds 1-9 was measured by FACS flow cytometry (see Table 2 ). 
Effects of 1 on Cell Cycle Progression of HT-29 Cells.
Lam-D was tested for effects on cell cycle progression in HT-29 tumor cells (Fig. 3) .
Cells were treated with the product (see Experimental Section) and then analyzed by flow cytometry to determine if the cell cycle had been arrested at a specific phase. A control set of untreated cells was also used.
Compared to the control cells (Fig. 3, panels 1a, c) , the cells treated with 1 (Fig. 3,   panels 1b, c) showed an arrest in G2/M progression. Hence, it was concluded that Lam-D inhibits cell cycle progression. Furthermore, conjugates 3 and 9 provoked cell cycle arrest in a greater extent. The results showed one single peak corresponding to the G2/M phase (see (Fig. 4 , see Experimental Section). The assay consists of detecting active caspases (caspase-3/7) using a commercially available colorimetric test.
All cell lines showed a high level of apoptotic cell death after treatment with compounds 1, 3 and 9 (Fig. 4, panels d−l) . A negative control of the assay was Notwithstanding, di-and tri-PEG conjugates were also synthesized. Di-and tri-PEG conjugates -which imply greater steric hindrance-were also synthesized, thereby demonstrating the robustness of our method. The pH-labile ester conjugates were prepared in 18 to 57% yields from the corresponding Lam-D phenolic precursors.
Conjugates (2-9), screened against normal BJ skin fibroblasts and three human cancer 
